$0.19
-0.01 (-5.85%)
Open$0.21
Previous Close$0.21
Day High$0.21
Day Low$0.19
52W High$2.79
52W Low$0.14
Volume—
Avg Volume2.29M
Market Cap14.75M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Sell
10 analysts
Price Target
+18,957.0% upside
Current
$0.19
$0.19
Target
$36.78
$36.78
$22.85
$36.78 avg
$42.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 16.46M | 14.50M | 15.97M |
| Net Income | 527.9K | 404.7K | 468.6K |
| Profit Margin | 3.2% | 2.8% | 2.9% |
| EBITDA | 822.7K | 875.9K | 889.3K |
| Free Cash Flow | 305.6K | 207.6K | 283.2K |
| Rev Growth | +9.2% | +19.8% | +5.1% |
| Debt/Equity | 1.41 | 1.41 | 1.44 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |